These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 16285032)

  • 1. Emerging trends in combinations of gefitinib and cytotoxic agents: new opportunities.
    Tabernero J; Macarulla T
    Onkologie; 2005 Oct; 28(10):467-70. PubMed ID: 16285032
    [No Abstract]   [Full Text] [Related]  

  • 2. Combining targeted agents in lung cancer.
    Belani CP; Adjei A
    Clin Lung Cancer; 2004 Nov; 6(3):138. PubMed ID: 15555212
    [No Abstract]   [Full Text] [Related]  

  • 3. Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy; hoping for it as a public domain.
    Hotta K; Ninomiya K; Takigawa N; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2015 Jun; 45(6):603-4. PubMed ID: 25920396
    [No Abstract]   [Full Text] [Related]  

  • 4. Third-line chemotherapy for advanced non-small-cell lung cancer--is there enough evidence to support its use?
    Yang CH
    J Chin Med Assoc; 2005 Apr; 68(4):160-1. PubMed ID: 15850063
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeted therapy at the end of life for patients with lung cancer.
    Wong AS; Teo C; Lim SW; Wong E; Soo RA; Chan N
    J Palliat Med; 2010 Aug; 13(8):945-8. PubMed ID: 20712464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of non-small cell lung cancer: focus on erlotinib. Foreword.
    Cappuzzo F
    Drugs; 2012 Jun; 72 Suppl 1():1-2. PubMed ID: 22712791
    [No Abstract]   [Full Text] [Related]  

  • 7. What went wrong with Iressa?
    Burton A
    Lancet Oncol; 2002 Dec; 3(12):708. PubMed ID: 12473493
    [No Abstract]   [Full Text] [Related]  

  • 8. [New era in cancer therapy. Gefitinib: small molecule--strong action].
    Arnheim K
    MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
    [No Abstract]   [Full Text] [Related]  

  • 9. Afatinib and chemotherapy in non-small-cell lung cancer.
    Brower V
    Lancet Oncol; 2016 Feb; 17(2):e47. PubMed ID: 26710711
    [No Abstract]   [Full Text] [Related]  

  • 10. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
    Ko JC; Ciou SC; Cheng CM; Wang LH; Hong JH; Jheng MY; Ling ST; Lin YW
    Carcinogenesis; 2008 Jul; 29(7):1448-58. PubMed ID: 18544565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line treatment of advanced non-small cell lung cancer.
    Gridelli C; Ardizzoni A; Ciardiello F; Hanna N; Heymach JV; Perrone F; Rosell R; Shepherd FA; Thatcher N; Vansteenkiste J; De Petris L; Di Maio M; De Marinis F
    J Thorac Oncol; 2008 Apr; 3(4):430-40. PubMed ID: 18379366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
    Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
    Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erlotinib plus bevacizumab is effective in EGFR-mutant NSCLC.
    Cancer Discov; 2014 Nov; 4(11):OF18. PubMed ID: 25367959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
    Yoshimura N; Kudoh S; Mitsuoka S; Yoshimoto N; Oka T; Nakai T; Suzumira T; Matusura K; Tochino Y; Asai K; Kimura T; Kawaguchi T; Hirata K
    Lung Cancer; 2015 Oct; 90(1):65-70. PubMed ID: 26238424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
    Gaafar RM; Surmont VF; Scagliotti GV; Van Klaveren RJ; Papamichael D; Welch JJ; Hasan B; Torri V; van Meerbeeck JP;
    Eur J Cancer; 2011 Oct; 47(15):2331-40. PubMed ID: 21802939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapy targets resistant non-small-cell lung cancers.
    Jenks S
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25421346
    [No Abstract]   [Full Text] [Related]  

  • 18. Gefitinib in the treatment of advanced non-small-cell lung cancer.
    Reck M
    Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.
    Costa DB
    Lung Cancer; 2007 Aug; 57(2):251-2. PubMed ID: 17566601
    [No Abstract]   [Full Text] [Related]  

  • 20. Navigating the changing multiple myeloma treatment landscape: clinical practice patterns of MM patients treated in- and outside German DSMM study group trials.
    Gengenbach L; Reinhardt H; Ihorst G; Ajayi S; Dold SM; Köhler M; Einsele H; Duyster J; Wäsch R; Engelhardt M
    Leuk Lymphoma; 2018 Nov; 59(11):2692-2699. PubMed ID: 29569975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.